Loading clinical trials...
Loading clinical trials...
Clinical Study on the Role of New Serum Tumor Autoantibodies in Predicting the Efficacy of Anti-PD-1 Immunotherapy in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Interventions
Serum tumor autoantibody detection
Start Date
September 1, 2020
Primary Completion Date
June 1, 2022
Completion Date
August 1, 2022
Last Updated
May 4, 2020
NCT06305754
NCT05198830
NCT07336732
NCT07190248
NCT07486219
NCT05692635
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions